Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GABA for ADHD and Seizures in Children with Epilepsy
NCT04144439Phase 4Recruiting
- Start
- Jul 2018
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gamma-aminobutyric acid in epilepsy and attention deficit hyperactivity disorder (ADHD). Primary endpoint: Number of seizures at 6 months. Started Jul 2018; status: recruiting.
02
Drugs
gamma-aminobutyric acid
03
Conditions
epilepsyattention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04144439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144439.